Pharma & Healthcare
Global Blood Cancer Drugs Market Research Report 2025
- Sep 09, 25
- ID: 498165
- Pages: 88
- Figures: 84
- Views: 5
This report aims to provide a comprehensive presentation of the global market for Blood Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Cancer Drugs.
The Blood Cancer Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Segment by Application
Leukemia
lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Cancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Blood Cancer Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Segment by Application
Leukemia
lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Cancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Blood Chemotherapy Drugs
1.2.3 Blood Targeted Therapy Drugs
1.3 Market by Application
1.3.1 Global Blood Cancer Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Leukemia
1.3.3 lymphoma
1.3.4 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Cancer Drugs Market Perspective (2020-2031)
2.2 Global Blood Cancer Drugs Growth Trends by Region
2.2.1 Global Blood Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Blood Cancer Drugs Historic Market Size by Region (2020-2025)
2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2026-2031)
2.3 Blood Cancer Drugs Market Dynamics
2.3.1 Blood Cancer Drugs Industry Trends
2.3.2 Blood Cancer Drugs Market Drivers
2.3.3 Blood Cancer Drugs Market Challenges
2.3.4 Blood Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Cancer Drugs Players by Revenue
3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2020-2025)
3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Blood Cancer Drugs Revenue
3.4 Global Blood Cancer Drugs Market Concentration Ratio
3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2024
3.5 Global Key Players of Blood Cancer Drugs Head office and Area Served
3.6 Global Key Players of Blood Cancer Drugs, Product and Application
3.7 Global Key Players of Blood Cancer Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Cancer Drugs Breakdown Data by Type
4.1 Global Blood Cancer Drugs Historic Market Size by Type (2020-2025)
4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2026-2031)
5 Blood Cancer Drugs Breakdown Data by Application
5.1 Global Blood Cancer Drugs Historic Market Size by Application (2020-2025)
5.2 Global Blood Cancer Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Blood Cancer Drugs Market Size (2020-2031)
6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Blood Cancer Drugs Market Size by Country (2020-2025)
6.4 North America Blood Cancer Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Cancer Drugs Market Size (2020-2031)
7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Blood Cancer Drugs Market Size by Country (2020-2025)
7.4 Europe Blood Cancer Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Drugs Market Size (2020-2031)
8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Cancer Drugs Market Size (2020-2031)
9.2 Latin America Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Blood Cancer Drugs Market Size by Country (2020-2025)
9.4 Latin America Blood Cancer Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Drugs Market Size (2020-2031)
10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen,
11.1.1 Amgen, Company Details
11.1.2 Amgen, Business Overview
11.1.3 Amgen, Blood Cancer Drugs Introduction
11.1.4 Amgen, Revenue in Blood Cancer Drugs Business (2020-2025)
11.1.5 Amgen, Recent Development
11.2 AstraZeneca PLC,
11.2.1 AstraZeneca PLC, Company Details
11.2.2 AstraZeneca PLC, Business Overview
11.2.3 AstraZeneca PLC, Blood Cancer Drugs Introduction
11.2.4 AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2020-2025)
11.2.5 AstraZeneca PLC, Recent Development
11.3 Astellas Pharma,
11.3.1 Astellas Pharma, Company Details
11.3.2 Astellas Pharma, Business Overview
11.3.3 Astellas Pharma, Blood Cancer Drugs Introduction
11.3.4 Astellas Pharma, Revenue in Blood Cancer Drugs Business (2020-2025)
11.3.5 Astellas Pharma, Recent Development
11.4 Bayer AG,
11.4.1 Bayer AG, Company Details
11.4.2 Bayer AG, Business Overview
11.4.3 Bayer AG, Blood Cancer Drugs Introduction
11.4.4 Bayer AG, Revenue in Blood Cancer Drugs Business (2020-2025)
11.4.5 Bayer AG, Recent Development
11.5 Bristol-Myers Squibb Company,
11.5.1 Bristol-Myers Squibb Company, Company Details
11.5.2 Bristol-Myers Squibb Company, Business Overview
11.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Introduction
11.5.4 Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2020-2025)
11.5.5 Bristol-Myers Squibb Company, Recent Development
11.6 Celgene Corporation,
11.6.1 Celgene Corporation, Company Details
11.6.2 Celgene Corporation, Business Overview
11.6.3 Celgene Corporation, Blood Cancer Drugs Introduction
11.6.4 Celgene Corporation, Revenue in Blood Cancer Drugs Business (2020-2025)
11.6.5 Celgene Corporation, Recent Development
11.7 Eli Lilly,
11.7.1 Eli Lilly, Company Details
11.7.2 Eli Lilly, Business Overview
11.7.3 Eli Lilly, Blood Cancer Drugs Introduction
11.7.4 Eli Lilly, Revenue in Blood Cancer Drugs Business (2020-2025)
11.7.5 Eli Lilly, Recent Development
11.8 F.Hoffmann-La Roche,
11.8.1 F.Hoffmann-La Roche, Company Details
11.8.2 F.Hoffmann-La Roche, Business Overview
11.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Introduction
11.8.4 F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2020-2025)
11.8.5 F.Hoffmann-La Roche, Recent Development
11.9 Johnson & Johnson,
11.9.1 Johnson & Johnson, Company Details
11.9.2 Johnson & Johnson, Business Overview
11.9.3 Johnson & Johnson, Blood Cancer Drugs Introduction
11.9.4 Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2020-2025)
11.9.5 Johnson & Johnson, Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Blood Cancer Drugs Introduction
11.10.4 Novartis Revenue in Blood Cancer Drugs Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer,
11.11.1 Pfizer, Company Details
11.11.2 Pfizer, Business Overview
11.11.3 Pfizer, Blood Cancer Drugs Introduction
11.11.4 Pfizer, Revenue in Blood Cancer Drugs Business (2020-2025)
11.11.5 Pfizer, Recent Development
11.12 Takeda Pharmaceutical Company Ltd,
11.12.1 Takeda Pharmaceutical Company Ltd, Company Details
11.12.2 Takeda Pharmaceutical Company Ltd, Business Overview
11.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Introduction
11.12.4 Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2020-2025)
11.12.5 Takeda Pharmaceutical Company Ltd, Recent Development
11.13 AbbVie
11.13.1 AbbVie Company Details
11.13.2 AbbVie Business Overview
11.13.3 AbbVie Blood Cancer Drugs Introduction
11.13.4 AbbVie Revenue in Blood Cancer Drugs Business (2020-2025)
11.13.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Blood Chemotherapy Drugs
1.2.3 Blood Targeted Therapy Drugs
1.3 Market by Application
1.3.1 Global Blood Cancer Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Leukemia
1.3.3 lymphoma
1.3.4 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Cancer Drugs Market Perspective (2020-2031)
2.2 Global Blood Cancer Drugs Growth Trends by Region
2.2.1 Global Blood Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Blood Cancer Drugs Historic Market Size by Region (2020-2025)
2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2026-2031)
2.3 Blood Cancer Drugs Market Dynamics
2.3.1 Blood Cancer Drugs Industry Trends
2.3.2 Blood Cancer Drugs Market Drivers
2.3.3 Blood Cancer Drugs Market Challenges
2.3.4 Blood Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Cancer Drugs Players by Revenue
3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2020-2025)
3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Blood Cancer Drugs Revenue
3.4 Global Blood Cancer Drugs Market Concentration Ratio
3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2024
3.5 Global Key Players of Blood Cancer Drugs Head office and Area Served
3.6 Global Key Players of Blood Cancer Drugs, Product and Application
3.7 Global Key Players of Blood Cancer Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Cancer Drugs Breakdown Data by Type
4.1 Global Blood Cancer Drugs Historic Market Size by Type (2020-2025)
4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2026-2031)
5 Blood Cancer Drugs Breakdown Data by Application
5.1 Global Blood Cancer Drugs Historic Market Size by Application (2020-2025)
5.2 Global Blood Cancer Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Blood Cancer Drugs Market Size (2020-2031)
6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Blood Cancer Drugs Market Size by Country (2020-2025)
6.4 North America Blood Cancer Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Cancer Drugs Market Size (2020-2031)
7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Blood Cancer Drugs Market Size by Country (2020-2025)
7.4 Europe Blood Cancer Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Drugs Market Size (2020-2031)
8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Cancer Drugs Market Size (2020-2031)
9.2 Latin America Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Blood Cancer Drugs Market Size by Country (2020-2025)
9.4 Latin America Blood Cancer Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Drugs Market Size (2020-2031)
10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen,
11.1.1 Amgen, Company Details
11.1.2 Amgen, Business Overview
11.1.3 Amgen, Blood Cancer Drugs Introduction
11.1.4 Amgen, Revenue in Blood Cancer Drugs Business (2020-2025)
11.1.5 Amgen, Recent Development
11.2 AstraZeneca PLC,
11.2.1 AstraZeneca PLC, Company Details
11.2.2 AstraZeneca PLC, Business Overview
11.2.3 AstraZeneca PLC, Blood Cancer Drugs Introduction
11.2.4 AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2020-2025)
11.2.5 AstraZeneca PLC, Recent Development
11.3 Astellas Pharma,
11.3.1 Astellas Pharma, Company Details
11.3.2 Astellas Pharma, Business Overview
11.3.3 Astellas Pharma, Blood Cancer Drugs Introduction
11.3.4 Astellas Pharma, Revenue in Blood Cancer Drugs Business (2020-2025)
11.3.5 Astellas Pharma, Recent Development
11.4 Bayer AG,
11.4.1 Bayer AG, Company Details
11.4.2 Bayer AG, Business Overview
11.4.3 Bayer AG, Blood Cancer Drugs Introduction
11.4.4 Bayer AG, Revenue in Blood Cancer Drugs Business (2020-2025)
11.4.5 Bayer AG, Recent Development
11.5 Bristol-Myers Squibb Company,
11.5.1 Bristol-Myers Squibb Company, Company Details
11.5.2 Bristol-Myers Squibb Company, Business Overview
11.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Introduction
11.5.4 Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2020-2025)
11.5.5 Bristol-Myers Squibb Company, Recent Development
11.6 Celgene Corporation,
11.6.1 Celgene Corporation, Company Details
11.6.2 Celgene Corporation, Business Overview
11.6.3 Celgene Corporation, Blood Cancer Drugs Introduction
11.6.4 Celgene Corporation, Revenue in Blood Cancer Drugs Business (2020-2025)
11.6.5 Celgene Corporation, Recent Development
11.7 Eli Lilly,
11.7.1 Eli Lilly, Company Details
11.7.2 Eli Lilly, Business Overview
11.7.3 Eli Lilly, Blood Cancer Drugs Introduction
11.7.4 Eli Lilly, Revenue in Blood Cancer Drugs Business (2020-2025)
11.7.5 Eli Lilly, Recent Development
11.8 F.Hoffmann-La Roche,
11.8.1 F.Hoffmann-La Roche, Company Details
11.8.2 F.Hoffmann-La Roche, Business Overview
11.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Introduction
11.8.4 F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2020-2025)
11.8.5 F.Hoffmann-La Roche, Recent Development
11.9 Johnson & Johnson,
11.9.1 Johnson & Johnson, Company Details
11.9.2 Johnson & Johnson, Business Overview
11.9.3 Johnson & Johnson, Blood Cancer Drugs Introduction
11.9.4 Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2020-2025)
11.9.5 Johnson & Johnson, Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Blood Cancer Drugs Introduction
11.10.4 Novartis Revenue in Blood Cancer Drugs Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer,
11.11.1 Pfizer, Company Details
11.11.2 Pfizer, Business Overview
11.11.3 Pfizer, Blood Cancer Drugs Introduction
11.11.4 Pfizer, Revenue in Blood Cancer Drugs Business (2020-2025)
11.11.5 Pfizer, Recent Development
11.12 Takeda Pharmaceutical Company Ltd,
11.12.1 Takeda Pharmaceutical Company Ltd, Company Details
11.12.2 Takeda Pharmaceutical Company Ltd, Business Overview
11.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Introduction
11.12.4 Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2020-2025)
11.12.5 Takeda Pharmaceutical Company Ltd, Recent Development
11.13 AbbVie
11.13.1 AbbVie Company Details
11.13.2 AbbVie Business Overview
11.13.3 AbbVie Blood Cancer Drugs Introduction
11.13.4 AbbVie Revenue in Blood Cancer Drugs Business (2020-2025)
11.13.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Blood Chemotherapy Drugs
Table 3. Key Players of Blood Targeted Therapy Drugs
Table 4. Global Blood Cancer Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Blood Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Blood Cancer Drugs Market Share by Region (2020-2025)
Table 8. Global Blood Cancer Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Blood Cancer Drugs Market Share by Region (2026-2031)
Table 10. Blood Cancer Drugs Market Trends
Table 11. Blood Cancer Drugs Market Drivers
Table 12. Blood Cancer Drugs Market Challenges
Table 13. Blood Cancer Drugs Market Restraints
Table 14. Global Blood Cancer Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Blood Cancer Drugs Market Share by Players (2020-2025)
Table 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Table 17. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Blood Cancer Drugs, Headquarters and Area Served
Table 20. Global Key Players of Blood Cancer Drugs, Product and Application
Table 21. Global Key Players of Blood Cancer Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Blood Cancer Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Blood Cancer Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Blood Cancer Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Blood Cancer Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Blood Cancer Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Blood Cancer Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Blood Cancer Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Blood Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Blood Cancer Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Amgen, Company Details
Table 47. Amgen, Business Overview
Table 48. Amgen, Blood Cancer Drugs Product
Table 49. Amgen, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 50. Amgen, Recent Development
Table 51. AstraZeneca PLC, Company Details
Table 52. AstraZeneca PLC, Business Overview
Table 53. AstraZeneca PLC, Blood Cancer Drugs Product
Table 54. AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 55. AstraZeneca PLC, Recent Development
Table 56. Astellas Pharma, Company Details
Table 57. Astellas Pharma, Business Overview
Table 58. Astellas Pharma, Blood Cancer Drugs Product
Table 59. Astellas Pharma, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 60. Astellas Pharma, Recent Development
Table 61. Bayer AG, Company Details
Table 62. Bayer AG, Business Overview
Table 63. Bayer AG, Blood Cancer Drugs Product
Table 64. Bayer AG, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 65. Bayer AG, Recent Development
Table 66. Bristol-Myers Squibb Company, Company Details
Table 67. Bristol-Myers Squibb Company, Business Overview
Table 68. Bristol-Myers Squibb Company, Blood Cancer Drugs Product
Table 69. Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 70. Bristol-Myers Squibb Company, Recent Development
Table 71. Celgene Corporation, Company Details
Table 72. Celgene Corporation, Business Overview
Table 73. Celgene Corporation, Blood Cancer Drugs Product
Table 74. Celgene Corporation, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 75. Celgene Corporation, Recent Development
Table 76. Eli Lilly, Company Details
Table 77. Eli Lilly, Business Overview
Table 78. Eli Lilly, Blood Cancer Drugs Product
Table 79. Eli Lilly, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 80. Eli Lilly, Recent Development
Table 81. F.Hoffmann-La Roche, Company Details
Table 82. F.Hoffmann-La Roche, Business Overview
Table 83. F.Hoffmann-La Roche, Blood Cancer Drugs Product
Table 84. F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 85. F.Hoffmann-La Roche, Recent Development
Table 86. Johnson & Johnson, Company Details
Table 87. Johnson & Johnson, Business Overview
Table 88. Johnson & Johnson, Blood Cancer Drugs Product
Table 89. Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 90. Johnson & Johnson, Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Blood Cancer Drugs Product
Table 94. Novartis Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Pfizer, Company Details
Table 97. Pfizer, Business Overview
Table 98. Pfizer, Blood Cancer Drugs Product
Table 99. Pfizer, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 100. Pfizer, Recent Development
Table 101. Takeda Pharmaceutical Company Ltd, Company Details
Table 102. Takeda Pharmaceutical Company Ltd, Business Overview
Table 103. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product
Table 104. Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 105. Takeda Pharmaceutical Company Ltd, Recent Development
Table 106. AbbVie Company Details
Table 107. AbbVie Business Overview
Table 108. AbbVie Blood Cancer Drugs Product
Table 109. AbbVie Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 110. AbbVie Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Blood Cancer Drugs Picture
Figure 2. Global Blood Cancer Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Blood Cancer Drugs Market Share by Type: 2024 VS 2031
Figure 4. Blood Chemotherapy Drugs Features
Figure 5. Blood Targeted Therapy Drugs Features
Figure 6. Global Blood Cancer Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Blood Cancer Drugs Market Share by Application: 2024 VS 2031
Figure 8. Leukemia Case Studies
Figure 9. lymphoma Case Studies
Figure 10. Multiple Myeloma Case Studies
Figure 11. Blood Cancer Drugs Report Years Considered
Figure 12. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Blood Cancer Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Blood Cancer Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Blood Cancer Drugs Market Share by Players in 2024
Figure 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2024
Figure 18. North America Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 20. United States Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 24. Germany Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Blood Cancer Drugs Market Share by Region (2020-2031)
Figure 32. China Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Amgen, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 48. AstraZeneca PLC, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 49. Astellas Pharma, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 50. Bayer AG, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 51. Bristol-Myers Squibb Company, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 52. Celgene Corporation, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 53. Eli Lilly, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 54. F.Hoffmann-La Roche, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 55. Johnson & Johnson, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 57. Pfizer, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 58. Takeda Pharmaceutical Company Ltd, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 59. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Blood Chemotherapy Drugs
Table 3. Key Players of Blood Targeted Therapy Drugs
Table 4. Global Blood Cancer Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Blood Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Blood Cancer Drugs Market Share by Region (2020-2025)
Table 8. Global Blood Cancer Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Blood Cancer Drugs Market Share by Region (2026-2031)
Table 10. Blood Cancer Drugs Market Trends
Table 11. Blood Cancer Drugs Market Drivers
Table 12. Blood Cancer Drugs Market Challenges
Table 13. Blood Cancer Drugs Market Restraints
Table 14. Global Blood Cancer Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Blood Cancer Drugs Market Share by Players (2020-2025)
Table 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Table 17. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Blood Cancer Drugs, Headquarters and Area Served
Table 20. Global Key Players of Blood Cancer Drugs, Product and Application
Table 21. Global Key Players of Blood Cancer Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Blood Cancer Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Blood Cancer Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Blood Cancer Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Blood Cancer Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Blood Cancer Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Blood Cancer Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Blood Cancer Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Blood Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Blood Cancer Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Blood Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Blood Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Amgen, Company Details
Table 47. Amgen, Business Overview
Table 48. Amgen, Blood Cancer Drugs Product
Table 49. Amgen, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 50. Amgen, Recent Development
Table 51. AstraZeneca PLC, Company Details
Table 52. AstraZeneca PLC, Business Overview
Table 53. AstraZeneca PLC, Blood Cancer Drugs Product
Table 54. AstraZeneca PLC, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 55. AstraZeneca PLC, Recent Development
Table 56. Astellas Pharma, Company Details
Table 57. Astellas Pharma, Business Overview
Table 58. Astellas Pharma, Blood Cancer Drugs Product
Table 59. Astellas Pharma, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 60. Astellas Pharma, Recent Development
Table 61. Bayer AG, Company Details
Table 62. Bayer AG, Business Overview
Table 63. Bayer AG, Blood Cancer Drugs Product
Table 64. Bayer AG, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 65. Bayer AG, Recent Development
Table 66. Bristol-Myers Squibb Company, Company Details
Table 67. Bristol-Myers Squibb Company, Business Overview
Table 68. Bristol-Myers Squibb Company, Blood Cancer Drugs Product
Table 69. Bristol-Myers Squibb Company, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 70. Bristol-Myers Squibb Company, Recent Development
Table 71. Celgene Corporation, Company Details
Table 72. Celgene Corporation, Business Overview
Table 73. Celgene Corporation, Blood Cancer Drugs Product
Table 74. Celgene Corporation, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 75. Celgene Corporation, Recent Development
Table 76. Eli Lilly, Company Details
Table 77. Eli Lilly, Business Overview
Table 78. Eli Lilly, Blood Cancer Drugs Product
Table 79. Eli Lilly, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 80. Eli Lilly, Recent Development
Table 81. F.Hoffmann-La Roche, Company Details
Table 82. F.Hoffmann-La Roche, Business Overview
Table 83. F.Hoffmann-La Roche, Blood Cancer Drugs Product
Table 84. F.Hoffmann-La Roche, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 85. F.Hoffmann-La Roche, Recent Development
Table 86. Johnson & Johnson, Company Details
Table 87. Johnson & Johnson, Business Overview
Table 88. Johnson & Johnson, Blood Cancer Drugs Product
Table 89. Johnson & Johnson, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 90. Johnson & Johnson, Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Blood Cancer Drugs Product
Table 94. Novartis Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 95. Novartis Recent Development
Table 96. Pfizer, Company Details
Table 97. Pfizer, Business Overview
Table 98. Pfizer, Blood Cancer Drugs Product
Table 99. Pfizer, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 100. Pfizer, Recent Development
Table 101. Takeda Pharmaceutical Company Ltd, Company Details
Table 102. Takeda Pharmaceutical Company Ltd, Business Overview
Table 103. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product
Table 104. Takeda Pharmaceutical Company Ltd, Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 105. Takeda Pharmaceutical Company Ltd, Recent Development
Table 106. AbbVie Company Details
Table 107. AbbVie Business Overview
Table 108. AbbVie Blood Cancer Drugs Product
Table 109. AbbVie Revenue in Blood Cancer Drugs Business (2020-2025) & (US$ Million)
Table 110. AbbVie Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Blood Cancer Drugs Picture
Figure 2. Global Blood Cancer Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Blood Cancer Drugs Market Share by Type: 2024 VS 2031
Figure 4. Blood Chemotherapy Drugs Features
Figure 5. Blood Targeted Therapy Drugs Features
Figure 6. Global Blood Cancer Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Blood Cancer Drugs Market Share by Application: 2024 VS 2031
Figure 8. Leukemia Case Studies
Figure 9. lymphoma Case Studies
Figure 10. Multiple Myeloma Case Studies
Figure 11. Blood Cancer Drugs Report Years Considered
Figure 12. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Blood Cancer Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Blood Cancer Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Blood Cancer Drugs Market Share by Players in 2024
Figure 16. Global Top Blood Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2024
Figure 18. North America Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 20. United States Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 24. Germany Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Blood Cancer Drugs Market Share by Region (2020-2031)
Figure 32. China Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Blood Cancer Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Blood Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Amgen, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 48. AstraZeneca PLC, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 49. Astellas Pharma, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 50. Bayer AG, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 51. Bristol-Myers Squibb Company, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 52. Celgene Corporation, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 53. Eli Lilly, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 54. F.Hoffmann-La Roche, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 55. Johnson & Johnson, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 56. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 57. Pfizer, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 58. Takeda Pharmaceutical Company Ltd, Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 59. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232